Cargando…

Screening of FDA Approved Drugs Against SARS-CoV-2 Main Protease: Coronavirus Disease

At the end of December 2019, a new strain of coronavirus was identified in the Wuhan city of Hubei province in China. Within a shorter period of time, an unprecedented outbreak of this strain was witnessed over the entire Wuhan city. This novel coronavirus strain was later officially renamed as COVI...

Descripción completa

Detalles Bibliográficos
Autores principales:	Balakrishnan, Vijayakumar, Lakshminarayanan, Karthik
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Netherlands 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7521772/ https://www.ncbi.nlm.nih.gov/pubmed/33013255 http://dx.doi.org/10.1007/s10989-020-10115-6

Ejemplares similares

Virtual screening and repurposing of FDA approved drugs against COVID-19 main protease
por: Kandeel, Mahmoud, et al.
Publicado: (2020)

Binary-QSAR guided virtual screening of FDA approved drugs and compounds in clinical investigation against SARS-CoV-2 main protease
por: OKTAY, Lalehan, et al.
Publicado: (2021)

Computational Insights and Virtual Screening of Repurposed FDA-Approved Drug Against SARS-CoV-2 Protease
por: Joel, C., et al.
Publicado: (2023)

In silico screening of FDA approved drugs reveals ergotamine and dihydroergotamine as potential coronavirus main protease enzyme inhibitors
por: Gurung, Arun Bahadur, et al.
Publicado: (2020)

Screening and evaluation of approved drugs as inhibitors of main protease of SARS-CoV-2
por: Tripathi, Praveen Kumar, et al.
Publicado: (2020)

Molecular docking and dynamics simulation of FDA approved drugs with the main protease from 2019 novel coronavirus
por: Odhar, Hasanain Abdulhameed, et al.
Publicado: (2020)

Virtual screening FDA approved drugs against multiple targets of SARS‐CoV‐2
por: Liang, Hualou, et al.
Publicado: (2021)

Virtual screening of approved drugs as potential SARS-CoV-2 main protease inhibitors
por: Jiménez-Alberto, Alicia, et al.
Publicado: (2020)

Repurposing of FDA-approved drugs as potential inhibitors of the SARS-CoV-2 main protease: Molecular insights into improved therapeutic discovery
por: Ray, Abhik Kumar, et al.
Publicado: (2022)

Repurposing of FDA Approved Drugs Against SARS-CoV-2 Papain-Like Protease: Computational, Biochemical, and in vitro Studies
por: Kulandaisamy, Rajkumar, et al.
Publicado: (2022)

Aminoglycosides as potential inhibitors of SARS-CoV-2 main protease: an in silico drug repurposing study on FDA-approved antiviral and anti-infection agents
por: Ahmed, Mohammad Z., et al.
Publicado: (2021)

Repurposing of US-FDA approved drugs against SARS-CoV-2 main protease (M(pro)) by using STD-NMR spectroscopy, in silico studies and antiviral assays
por: Khan, Abdul Mateen, et al.
Publicado: (2023)

Repurposing Screens of FDA-Approved Drugs Identify 29 Inhibitors of SARS-CoV-2
por: Ku, Keun Bon, et al.
Publicado: (2020)

Exploring the anti-SARS-CoV-2 main protease potential of FDA approved marine drugs using integrated machine learning templates as predictive tools
por: Attiq, Naila, et al.
Publicado: (2022)

Potential Inhibitors of SARS-CoV-2 Main Protease (M(pro)) Identified from the Library of FDA-Approved Drugs Using Molecular Docking Studies
por: Verma, Dipesh Kumar, et al.
Publicado: (2022)

Identification of Antiviral Drug Candidates against SARS-CoV-2 from FDA-Approved Drugs
por: Jeon, Sangeun, et al.
Publicado: (2020)

Antiviral Efficacies of FDA-Approved Drugs against SARS-CoV-2 Infection in Ferrets
por: Park, Su-Jin, et al.
Publicado: (2020)

Discovery and mechanism of action of Thonzonium bromide from an FDA-approved drug library with potent and broad-spectrum inhibitory activity against main proteases of human coronaviruses
por: Wang, Ruyu, et al.
Publicado: (2023)

In silico molecular docking analysis for repurposing approved antiviral drugs against SARS-CoV-2 main protease
por: Khater, Ibrahim, et al.
Publicado: (2021)

In Silico Evaluation of the Effectivity of Approved Protease Inhibitors against the Main Protease of the Novel SARS-CoV-2 Virus
por: Eleftheriou, Phaedra, et al.
Publicado: (2020)

Insilico drug repurposing using FDA approved drugs against Membrane protein of SARS-CoV-2
por: Peele, K.Abraham, et al.
Publicado: (2021)

Repurposing FDA-approved drugs against multiple proteins of SARS-CoV-2: An in silico study
por: Akinlalu, Alfred Olaoluwa, et al.
Publicado: (2021)

Screening of an FDA-Approved Library for Novel Drugs against Y. pestis
por: Gur, David, et al.
Publicado: (2021)

Computation screening and molecular docking of FDA approved viral protease inhibitors as a potential drug against COVID-19
por: Absalan, Abdorrahim, et al.
Publicado: (2020)

Computational screening for potential drug candidates against the SARS-CoV-2 main protease
por: Silva Andrade, Bruno, et al.
Publicado: (2020)

The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro
por: Caly, Leon, et al.
Publicado: (2020)

Drug repurposing screens reveal cell-type-specific entry pathways and FDA-approved drugs active against SARS-Cov-2
por: Dittmar, Mark, et al.
Publicado: (2021)

Accelerating the repurposing of FDA-approved drugs against coronavirus disease-19 (COVID-19)
por: De Vita, Simona, et al.
Publicado: (2020)

Convergent evidence for the antiviral effects of several FDA-approved phenothiazine antipsychotics against SARS-CoV-2 and other coronaviruses
por: Machado-Vieira, Rodrigo, et al.
Publicado: (2021)

The Main Protease of SARS-CoV-2 as a Target for Phytochemicals against Coronavirus
por: Issa, Shaza S., et al.
Publicado: (2022)

Host-Directed FDA-Approved Drugs with Antiviral Activity against SARS-CoV-2 Identified by Hierarchical In Silico/In Vitro Screening Methods
por: Ginex, Tiziana, et al.
Publicado: (2021)

Targeting the SARS-CoV-2 main protease using FDA-approved Isavuconazonium, a P2–P3 α-ketoamide derivative and Pentagastrin: An in-silico drug discovery approach
por: Achilonu, Ikechukwu, et al.
Publicado: (2020)

Computational models identify several FDA approved or experimental drugs as putative agents against SARS-CoV-2
por: Bobrowski, Tesia, et al.
Publicado: (2020)

FDA approved drugs with pharmacotherapeutic potential for SARS-CoV-2 (COVID-19) therapy
por: Drożdżal, Sylwester, et al.
Publicado: (2020)

Inhibition of the replication of SARS-CoV-2 in human cells by the FDA-approved drug chlorpromazine
por: Plaze, Marion, et al.
Publicado: (2021)

Several FDA-Approved Drugs Effectively Inhibit SARS-CoV-2 Infection in vitro
por: Xiong, Hua-Long, et al.
Publicado: (2021)

Identification of FDA-approved drugs against SARS-CoV-2 RNA-dependent RNA polymerase (RdRp) through computational virtual screening
por: Jade, Dhananjay, et al.
Publicado: (2022)

Identification of FDA-approved bifonazole as a SARS-CoV-2 blocking agent following a bioreporter drug screen
por: Taha, Zaid, et al.
Publicado: (2022)

In-silico screening of naturally derived phytochemicals against SARS-CoV Main protease
por: Mostafa, Islam, et al.
Publicado: (2021)

Identification of FDA approved drugs against SARS-CoV-2 RNA dependent RNA polymerase (RdRp) and 3-chymotrypsin-like protease (3CLpro), drug repurposing approach
por: Molavi, Zahra, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_fg99cb0m55i5a9ahf9hkr1sceg